Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) Shares Outstanding (Weighted Average): 2020-2024

Historic Shares Outstanding (Weighted Average) for Relay Therapeutics (RLAY) over the last 5 years, with Dec 2024 value amounting to $167.4 million.

  • Relay Therapeutics' Shares Outstanding (Weighted Average) rose 28.77% to $172.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $172.4 million, marking a year-over-year increase of 28.77%. This contributed to the annual value of $167.4 million for FY2024, which is 35.79% up from last year.
  • Latest data reveals that Relay Therapeutics reported Shares Outstanding (Weighted Average) of $167.4 million as of FY2024, which was up 35.79% from $123.3 million recorded in FY2023.
  • Relay Therapeutics' Shares Outstanding (Weighted Average)'s 5-year high stood at $167.4 million during FY2024, with a 5-year trough of $90.0 million in FY2020.
  • For the 3-year period, Relay Therapeutics' Shares Outstanding (Weighted Average) averaged around $137.2 million, with its median value being $123.3 million (2023).
  • Data for Relay Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY spiked of 35.79% (in 2024) over the last 5 years.
  • Yearly analysis of 5 years shows Relay Therapeutics' Shares Outstanding (Weighted Average) stood at $90.0 million in 2020, then grew by 20.07% to $108.0 million in 2021, then rose by 11.89% to $120.9 million in 2022, then rose by 1.96% to $123.3 million in 2023, then soared by 35.79% to $167.4 million in 2024.